Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial
Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.